CBDV Cannabidivarin
Grades as of 9 August 2026 · check cbgatlas.com/card/cbdv
Specimen
- Formula
- C₁₉H₂₆O₂
- Molar mass
- ≈ 286.4 g/mol
- Class
- Propyl (varin) homolog of CBD
- Intoxicating
- Not reported at trial doses
- Evidence base
- Tested in people; primary endpoints missed
- Approved use
- None in any jurisdiction
- Registry status
- Papers cited in prose, ungraded
- CAS
- 24274-48-4
- Studies in our registry
- 0 · catalogue in progress
In the family
CBD’s propyl analog; forms when heat decarboxylates CBDVA.
The record cited in prose · ungraded
Established
- Chemical identity C₁₉H₂₆O₂ (≈ 286.4 g/mol).
- Biosynthetic branch Decarboxylating CBGVA gives CBGV; getting to CBDV takes an enzyme first.
- Trials in people have been conducted CBDV has had what few minor cannabinoids get: a sponsored clinical programme.
Not yet established
- Efficacy in focal seizures Not established, although it has been tested.
- Efficacy in HIV-associated neuropathic pain Not established.
- Any approved use, anywhere No jurisdiction has approved a CBDV medicine for any indication, and prescribed antiseizure medication has no CBDV stand-in.
Cardiovascular note grade: grade: Hypothesized
CBG may influence blood pressure via α2-adrenoceptor activity; the direction and magnitude of any human effect are uncharacterized. Mechanistic plausibility only: the receptor activity has been measured in the laboratory, and no study has measured a blood-pressure effect of CBG in a person. A CBG finding, printed here because CBDV shares the family; it does not transfer to CBDV. If you take blood-pressure medication or have a cardiovascular condition, consult a clinician first.
Informational only, not medical advice. Nothing here diagnoses, treats, cures or prevents any disease. Report a safety event. Peregrine Biopharma funds the platform and holds no editorial authority.